For example, NPM1 mutations and double CEBPA mutations are associated with favorable prognosis in cytogenetically normal AML (CN-AML) 2, 3, while DNMT3A and WT1 mutations are adverse prognostic factors 4, 5. This evidence concerns the gene NPM1 and acute myeloid leukemia.